User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Drug development programs have undertaken significant efforts to identify toxic events at the earliest opportunity during the development process. They have moved from predominantly observational science at the level of disease-specific testing to more predictive models focused on target-specific, mechanism-based biological observations.
Identifying potential toxicity at an early stage during drug discovery can save both time and development costs and, most importantly, reduce the likelihood of late stage failure.
Drug-induced toxicities, with hepatotoxicity and cardiotoxicity being the most common, are the main cause for the withdrawal of drugs from the market. Potential drug candidates often fail because of unacceptable levels of toxicity. Therefore, prediction of potential toxicities of candidate compounds is of great importance for successful drug development.
Compared to in vivo studies, in vitro toxicity testing is believed to be more useful at an early stage of drug development due to short turnaround times and relatively low cost.
Check out our application notes below and find out how our flow cytometry solutions can help improve your in vitro toxicity testing!
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.
